Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty

Cornea

Volumn 27, Issue 3, 2008, Pages 314-319

  Holland, Edward J ^a,f   Lane, Stephen S ^b   Kim, Terry ^c   Raizman, Michael ^d   Dunn, Steven ^e  

^a Cincinnati Eye Institute   (United States)

^b Associated Eye Care   (United States)

^c DUKE UNIVERSITY EYE CENTER   (United States)

^d OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

^e Michigan Cornea Consultants   (United States)

^f Cornea Services ^*  (United States)

Author keywords

Gatifloxacin; Keratoplasty; Moxifloxacin; Ocular penetration; Ocular pharmacokinetics

Indexed keywords

GATIFLOXACIN; MOXIFLOXACIN;

ADULT; AGED; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG TISSUE LEVEL; EPITHELIZATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KERATOPLASTY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; AQUEOUS HUMOR; AZA COMPOUNDS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORNEA; FEMALE; FLUOROQUINOLONES; HUMANS; KERATOPLASTY, PENETRATING; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; QUINOLINES; TISSUE DISTRIBUTION; WOUND HEALING;

EID: 41149160857     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181608561     Document Type: Article

References (32)

1. Solomon R, Donnenfeld ED, Azar DT, et al. Infectious keratitis after laser in situ keratomileusis: results of an ASCRS survey. J Cataract Refract Surg. 2003;29:2001-2006.
2. Han DP, Wisniewski SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol. 1996;122:1-17.
3. Eifrig CWG, Flynn HW Jr, Scott IU, et al. Acute-onset postoperative endophthalmitis: review of incidence and visual outcomes (1995-2001). Ophthalmic Surg Lasers. 2002;33:373-378.
4. Miller JJ, Scott IU, Flynn HW Jr, et al. Acute-onset endophthalmitis after cataract surgery (2000-2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol. 2005;139:983-987.
5. Leaming DV. Practice styles and preferences of ASCRS members - 2003 survey. J Cataract Refract Surg. 2004;30:892-900.
6. Allergan. Zymar (Gatifloxacin Ophthalmic Solution) 0.3% [Package Insert]. Irvine, CA: Allergan; 2004.
7. Alcon Laboratories. Vigamox (Moxifloxacin Hydrochloride Ophthalmic Solution 0.5%) as Base [Package Insert]. Fort Worth, TX: Alcon Laboratories; 2004.
8. Donnenfeld ED, Kim T, Holland EJ, et al. ASCRS white paper: management of infectious keratitis following laser in situ keratomileusis. J Cataract Refract Surg. 2005;31:2008-2011.
9. Mather R, Karenchak LM, Romanowski EG, et al. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463-466.
10. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136:500-505.
11. Stroman DW, Cupp G, Dahlin DC, et al. Human ocular concentrations following topical fluoroquinolone administration relative to susceptibility of ocular pathogens. Invest Ophthalmol Vis Sci. 2006;47.
12. Pestova E, Millichap JJ, Noskin GA, et al. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J Antimicrob Chemother. 2000;45:583-590.
13. Kishii R, Takei M, Fukuda H, et al. Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2003;47:77-81.
14. Strahilevitz J, Hooper DC. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin. Antimicrob Agents Chemother. 2005;49:1949-1956.
15. Caballero AR, Marquart ME, O'Callaghan RJ, et al. Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo. Curr Eye Res. 2006;31:23-29.
16. Dajcs JJ, Thibodeaux BA, Marquart ME, et al. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis. Antimicrob Agents Chemother. 2004;48:1948-1952.
17. Donnenfeld RS, Perry HD, Solomon R, et al. A comparison of gatifloxacin to ciprofloxacin in the prophylaxis of Streptococcus pneumoniae in rabbits in a LASIK model. Eye Contact Lens. 2006;32:46-50.
18. Kowalski RP, Romanowski EG, Mah FS, et al. Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model. Am J Ophthalmol. 2004;138:33-37.
19. Fernández de Castro LE, Sandoval HP, Bartholomew LR, et al. Prevention of Staphylococcus aureus endophthalmitis with topical gatifloxacin in a rabbit prophylaxis model. J Ocul Pharmacol Ther. 2006;22:132-138.
20. Katz HR, Masket S, Lane SS, et al. Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. Cornea. 2005;24:955-958.
21. Hing JP, Woolfrey SG, Greenslade D, et al. Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data. J Pharmacokinet Pharmacodyn. 2001;28:465-479.
22. Nedelman JR, Gibiansky E, Lau DTW. Applying Bailer's method for AUC confidence intervals to sparse sampling. Pharm Res. 1995;12:124-128.
23. Robertson SM, Curtis MA, Schlech BA, et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol. 2005;50(Suppl 1):S32-S45.
24. Kim DH, Stark WJ, O'Brien TP, et al. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology. 2005;112:1992-1996.
25. Solomon R, Donnenfeld ED, Perry HD, et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology. 2005;112:466-469.
26. McCulley JP, Caudle D, Aronowicz JD, et al. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology. 2006;113:955-959.
27. Healy DP, Holland EJ, Nordlund ML, et al. Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in human corneal stromal tissue and aqueous humor after topical administration. Cornea. 2004;23:255-263.
28. Hayes S, Boote C, Tuft SJ, et al. A study of corneal thickness, shape and collagen organisation in keratoconus using videokeratography and x-ray scattering techniques. Exp Eye Res. 2007;84:423-434.
29. Rusinko A, May J, Liao J, et al. A study of the enhanced corneal penetration of moxifloxacin. Invest Ophthalmol Vis Sci. 2004;45:E4907.
30. Liu W, Liu QF, Perkins R, et al. Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: physicochemical properties that regulate penetration of quinolone antimicrobials. Antimicrob Agents Chemother. 1998;42:1417-1423.
31. Schlech BA, Stroman DW, Alfonso E, et al. The threat of atypical mycobacteria in ophthalmology. Abstract 21 presented at the 2003 Ocular Microbiology and Immunology Group, Anaheim, CA, November 15, 2003.
32. Owen GR, Dembinska O, Stout KR, et al. Corneal penetration and changes in corneal permeability of moxifloxacin versus gatifloxacin. Invest Ophthalmol Vis Sci. 2004;45:E4910.